Abstract

Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials

Author(s): Mueller Claudia, Dietel Elde, Heynen Severin R, Nalenz Heiko, Goldbach Pierre, Mahler Hanns-Christian, Schmidt Johannes, Grauschopf Ulla, Schoenhammer Karin

Issue: May/Jun 2015 - Volume 19, Number 3

Page(s): 261-267

Download in electronic PDF format for $75
  • Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials Page 1
  • Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials Page 2
  • Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials Page 3
  • Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials Page 4
  • Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials Page 5
  • Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials Page 6
  • Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials Page 7

Abstract

MabThera is an essential component of the standard-of–care regimens in the treatment of non-Hodgkin lymphoma and Chronic Lymphatic Leukemia. MabThera for subcutaneous injection is a novel line extension that has been approved by the European Medicines Agency for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma. This study aimed to evaluate in-use stability data of MabThera subcutaneous drug-product solution in single-use syringes for subcutaneous administration according to the European Medicines Agency guideline. The drug-product solution was exposed to material contact surfaces of five different administration setups commonly used in subcutaneous drug delivery. MabThera subcutaneous was transferred under aseptic conditions into polypropylene and polycarbonate syringes and stored for 1, 2, and 4 weeks at 2°C to 8°C followed by 24 hours at 30°C. After storage, subcutaneous administration was simulated and MabThera subcutaneous drug-product solution quality attributes were evaluated by using compendial physico-chemical tests, as well as suitable and validated molecule- and formulation-specific analytical methods. MabThera subcutaneous vials were treated and analyzed in parallel. The physicochemical results of MabThera subcutaneous in the different setups were comparable to the control for all timepoints. No change in drug-product quality after storage and simulated administration was found compared to the control. However, since single-dose products do not contain preservatives, microbial contamination and growth needs to be avoided and product sterility needs to be ensured. The results showed that MabThera subcutaneous remains compatible and stable, from a physico-chemical perspective, for up to 4 weeks at 2°C to 8°C followed by 24 hours at 30°C with the contact materials tested in this study. In order to avoid and minimize microbial growth, MabThera subcutaneous should be used immediately after removal from the original packaging container and strict aseptic handling conditions need to be followed.

Related Keywords

  • MabThera drug product solution
  • rituximab
  • CD20
  • lymphoma
  • B-cell leukemia
  • autoimmune disorders
  • intravenous immunoglobulin
  • subcutaneous administration
  • hyaluronidase
  • stability

Related Categories

  • CANCER AND AIDS
  • PEER-REVIEWED
  • STABILITIES, COMPATIBILITIES
  • STERILE PREPARATIONS
  • ALLERGY/IMMUNOLOGY/INFLAMMATION

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
May/Jun 2015
Pg. 261-267
Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials
Author(s): Mueller Claudia, Dietel Elde, Heynen Severin R, Nalenz Heiko, Goldbach Pierre, Mahler Hanns-Christian, Schmidt Johannes, Grauschopf Ulla, Schoenhammer Karin
May/Jun 2003
Pg. 170-174
Five Compounds for Treating Diabetes-Related Conditions
Author(s): Meece Jerry
Nov/Dec 2023
Pg. 474-481
Nonsterile Basics of Compounding: Using U.S. Food and Drug Administration-approved Commercial Products as Ingredients
Author(s): Allen Loyd V Jr
Jan/Feb 2004
Pg. 46-48
Basics of Compounding for Disorders of the External Ear
Author(s): Allen Loyd V Jr
Nov/Dec 2022
Pg. 446-466
Compounding with Biotechnology Products, Part 2: Product-specific Considerations
Author(s): Allen Loyd V Jr
Sep/Oct 2017
Pg. 356
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Author(s): Allen Loyd V Jr
Nov/Dec 2017
Pg. 481-486
Basics of Compounding: Compounding Irrigation Solutions for Sterile and Nonsterile Preparations
Author(s): Allen Loyd V Jr
Jul/Aug 2011
Pg. 302-307
Treating Inner Ear Disorders with Intratympanic Drug Administration
Author(s): McElhiney Linda F
Sep/Oct 2022
Pg. 385-395
Compounding with Biotechnology Products, Part 1: General Considerations
Author(s): Allen Loyd V Jr
Sep/Oct 2014
Pg. 379-380
Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A
Author(s): Blankenship Cynthia E
Jul/Aug 2016
Pg. 347-350
Long-term Stability of Vancomycin Hydrochloride in Oral Solution: The Brand Name Versus a Generic Product
Author(s): Huvelle Sophie, Godet Marie, Hecq Jean-Daniel, Gillet Patricia, Jamart Jacques, Galanti Laurence M
Jan/Feb 2016
Pg. 41-45
Formulation and Stability of Solutions
Author(s): Akers Michael J
Jul/Aug 2013
Pg. 270-280
Jet Injection Devices for the Needle-free Administration of Compounds, Vaccines, and Other Agents
Author(s): Logomasini Mark A, Stout Richard R, Ron Marcinkoski
Jul/Aug 2001
Pg. 246-253
Quality Assurance for Sterile Products
Author(s): Kastango Eric S, Douglass Kate
Jul/Aug 2002
Pg. 311-315
Compatibility Screening of Bivalirudin During Simulated Y-Site Administration with Other Drugs
Author(s): Trissel Lawrence A, Saenz Christopher
May/Jun 1997
Pg. 150-151
Drug Products and Drug Packaging for the Elderly
Author(s): Allen Loyd V Jr
Sep/Oct 2015
Pg. 367-373
Compounding Pharmacies' Potential to Create Graft Storage Solutions for Bypass Surgeries
Author(s): Guth Michael AS
Jul/Aug 2016
Pg. 351
View Sample
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Author(s): Allen Loyd V Jr
Jul/Aug 2017
Pg. 301-308
Basics of Sterile Compounding: Excipients Used in Injections
Author(s): Akers Michael J
Jul/Aug 2003
Pg. 292-293
How to Handle a Product Recall
Author(s): Allen Loyd V Jr